Story
Southern Cross Acquisition I Corp. Closes $115 Million IPO on Nasdaq

Summary
The special purpose acquisition company raised $115 million by offering 11.5 million units at $10.00 each, with proceeds placed in a trust account for a future business combination.
Southern Cross Acquisition I Corp. (Nasdaq: NCOOU), a special purpose acquisition company (SPAC), has closed its initial public offering, raising $115 million in gross proceeds. The Cayman Islands-incorporated firm's units began trading on the Nasdaq Global Market on July 21, 2026, with the offering officially closing on July 22.
Offering Details
The IPO consisted of the sale of 11,500,000 units at a price of $10.00 per unit. This total includes 1,500,000 units issued as part of the full exercise of the underwriters’ over-allotment option. According to the company's announcement, the proceeds have been placed into a trust account pending a future acquisition.
Each unit sold in the IPO contains:
- One ordinary share
- One redeemable warrant to purchase one ordinary share at an exercise price of $11.50
- One right to receive one-quarter of one ordinary share upon the completion of an initial business combination
AdOnce the securities comprising the units begin separate trading, the ordinary shares, warrants, and rights are expected to be listed on Nasdaq under the symbols "NCO," "NCOOW," and "NCOOR," respectively. The company also completed a concurrent private placement of 239,300 units, raising an additional $2,393,000.
Strategy and Advisors
As a blank check company, Southern Cross Acquisition I Corp. was formed to effect a merger, asset acquisition, or other business combination with an operating company. The company stated that its search for a target will not be limited to a specific industry or geographic region.
D. Boral Capital LLC acted as the sole book-running manager for the offering. The company was represented by Robinson & Cole LLP, while Norton Rose Fulbright US LLP served as legal counsel to the underwriter. The company is expected to file an audited balance sheet as of July 22, 2026, with the U.S. Securities and Exchange Commission via a Form 8-K.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.